Zai Lab Limited has announced plans for a pivotal clinical trial of ZL-1310, a Delta-like ligand 3 (DLL3) antibody-drug conjugate $(ADC)$, aimed at treating patients with extensive-stage small cell lung cancer (ES-SCLC). The company intends to begin the randomized registrational study later this year, comparing the selected dose of ZL-1310 against the current standard of care for second-line treatment. This follows updated data from an ongoing global Phase 1a/1b trial, which demonstrated a favorable safety profile and promising efficacy. Additionally, Zai Lab is actively enrolling patients in a front-line SCLC study and in other neuroendocrine carcinomas, with further data updates anticipated in the coming months. An investor conference call and webcast to discuss these developments is scheduled for June 2, 2025.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。